The Rise Of Computational Biology In Biopharma

By Matthew Pillar, Editor, Bioprocess Online

Life Science Leader Editorial Director Dan Schell’s request of me to write about “the” trend in biopharma was a pretty tall order. There’s a lot going on right now. I could go long on the turbulent biopharma economy and its impact on the innovation coming out of emerging biotech companies. I could rehash the broken supply chain and why its prognosis is not promising. I could write about RNA-anything and likely generate clicks. I could dig into the (still) nascent promise (and peril) of cell and gene therapies. But all that stuff is thoroughly covered regularly around here. It’s all important, but I thought I’d peel a layer off the onion to reveal a trend that’s gaining momentum and having a positive impact during a somewhat negative biopharma news cycle: computational biology.